Language
English
Publication Date
1-3-2023
Journal
Cancer Immunology Research
DOI
10.1158/2326-6066.CIR-22-0116
PMID
36260656
PMCID
PMC10544831
PubMedCentral® Posted Date
10-2-2023
PubMedCentral® Full Text Version
Author MSS
Abstract
VISTA is a premier target for cancer treatment due to its broad expression in many cancer types and enhanced expression upon development of adaptive immune checkpoint resistance. In the CT26 colorectal cancer model, monotherapy of small tumors with anti-VISTA resulted in slowed tumor growth. In a combination therapy setting, large CT26 tumors showed complete adaptive resistance to anti-PD-1/CTLA-4, but inclusion of anti-VISTA led to rejection of half the tumors. Mechanisms of enhanced anti-tumor immunity were investigated using scRNA-seq, multiplex image analysis and flow cytometry of the tumor immune infiltrate. In both treatment models, anti-VISTA upregulated stimulated antigen-presentation pathways and reduced myeloid mediated suppression. Imaging revealed an anti-VISTA stimulated increase in contacts between T cells and myeloid cells, further supporting the notion of increased antigen presentation. scRNA-seq of tumor-specific CD8+ T cells revealed that anti-VISTA therapy induced T-cell pathways highly distinct from and complementary to those induced by anti-PD-1 therapy. Whereas anti-CTLA-4/PD-1 expanded progenitor exhausted CD8+ T-cell subsets, anti-VISTA promoted costimulatory genes and reduced regulators of T-cell quiescence. Notably, this is the first report of a checkpoint regulator impacting CD8+ T-cell quiescence, and the first indication that quiescence may be a target in the context of T-cell exhaustion and in cancer. This study builds a foundation for all future studies on the role of anti-VISTA in the development of anti-tumor immunity and provide important mechanistic insights that strongly supports use of anti-VISTA to overcome the adaptive resistance seen in contemporary treatments involving PD-1 and/or CTLA-4.
Keywords
Humans, Immune Checkpoint Inhibitors, B7 Antigens, Neoplasms, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Immunoglobulins
Published Open-Access
yes
Recommended Citation
Schaafsma, Evelien; Croteau, Walburga; ElTanbouly, Mohamed; et al., "VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance" (2023). Faculty, Staff and Students Publications. 6226.
https://digitalcommons.library.tmc.edu/baylor_docs/6226